[Recent advances in PPARgamma research].

PPARgamma is a member of the nuclear receptor superfamily and a molecular target of the thiazolidinedione class of antidiabetic drugs. PPARgamma was initially characterized as a central regulator of adipocyte differentiation. Recent advances in PPARgamma research have revealed diverse pathophysiological actions of PPARgamma such as regulation of expression of adipokines and inflammatory mediators, adipose tissue macrophage polarization, atherosclerosis formation and bone development. Here, we highlight recent advances in our current understanding the biological actions of PPARgamma.